Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/08—Bronchodilators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/16—Central respiratory analeptics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/08—Antiseborrheics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/14—Decongestants or antiallergics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
  • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
  • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
  • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
  • C07D221/04—Ortho- or peri-condensed ring systems
  • C07D221/06—Ring systems of three rings
  • C07D221/10—Aza-phenanthrenes
  • C07D221/12—Phenanthridines
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

• the invention relates to novel 6-phenylphenanthridines, which are used in the pharmaceutical industry for the production of medicaments.
• the invention thus relates to compounds of the formula I,
• R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy
• R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy, or in which
• R1 and R2 together are a 1-2C-alkylenedioxy group
• R3 is hydrogen or 1-4C-alkyl
• R31 is hydrogen or 1-4C-alkyl, or in which
• R3 and R31 together are a 1-4C-alkylene group
• R4 is hydrogen or 1-4C-alkyl
• R5 is hydrogen
• R51 is hydrogen, or in which
• R6 is 0-R7, S-R8, C(0)-R9, CH 2 -R10, S(0) 2 -aryl, 0-S(0) 2 -R11 , pyrrolidin-1-yl, pyrrolidin-1-yl-2-one, pyrrolidin-1-yl-2,5-dione, piperidin-1-yl, piperidin-1-yl-2-one or piperidin-1 -yl-2,6-dione, where
• R7 is 3-7C-cycloalkyl, 3-7C-cycloalkylmethyI, 1-4C-alkoxy-1-4C-alkyl, aryl or phenyl-1-4C-alkyl,
• R8 is hydrogen, 1-4C-alkyl, 1-4C-alkylcarbonyl, arylcarbonyl, trifluoromethyl, difluoromethyl, trichlo- romethyl or phenyl,
• R9 is 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-methylpiperazinyl, 4-morpholinyl or aryl,
• R10 is hydroxyl, halogen, cyano, carboxyl, 1-4C-alkoxy, phenoxy, 1-4C-alkoxycarbonyl, aminocar- bonyl, mono- or di-1-4C-alkylaminocarbonyl, N(R15)R16 or 1-4C-alkylcarbonylamino, and
• R11 is 1-4C-alkyl, amino, mono- or di-1-4C-a!kylamino or aryl, aryl is phenyl, pyridyl or R12-substituted phenyl, where
• R12 is hydroxyl, halogen, carboxyl, nitro, amino, cyano, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonylamino, 1-4C-alkylcarbonyloxy or aminocarbonyl,
• R13 is hydrogen, hydroxyl, halogen, cyano, nitro, amino, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, phenyl, phenyl-1-4C-alkyl, C(O)-OR14, C(0)-N(R15)R16, N(R17)R18, S(0) 2 -R19, S(0) 2 -N(R15)R16 or has one of the meanings of R6, where
• R14 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl,
• R15 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl,
• R16 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl or aryl, or where R15 and R16, together and including the nitrogen atom to which both are bonded, represent a 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-methylpiperazin-1-yl, 1-hexahydroazepinyl or 4-morpholinyl radical,
• R17 is hydrogen, 1 -4C-alkyl, S(0) 2 -R19 or S(0) 2 -aryl, R18 is 1-4C-alkyl, 1-4C-alkylcarbonyl, 3-7C-cycloalkylcarbonyl, 3-7C-cycloalkylmethylcarbonyl,
• R19 is 1-4C-alkyl
• R20 is hydrogen, hydroxyl, halogen, nitro, amino, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy,
• 1-4C-Alkyl represents a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are the butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl and preferably the ethyl and methyl radicals.
• 1-4C-Alkoxy represents radicals which, in addition to the oxygen atom, contain a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy and preferably the ethoxy and methoxy radicals.
• 3-7C-Cycloalkoxy represents cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and cyclo- heptyloxy, of which cyclopropyloxy, cyclobutyloxy and cyclopentyloxy are preferred.
• 3-7C-Cycloalkylmethoxy represents cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cy- clohexylmethoxy and cycloheptylmethoxy, of which cyclopropylmethoxy, cyclobutylmethoxy and cyclopentylmethoxy are preferred.
• fluorine-substituted 1-4C-alkoxy for example, the 2,2,3,3,3-penta- fluoropropoxy, the perfluoroethoxy, the 1 ,2,2-trifluoroethoxy, in particular the 1 ,1 ,2,2-tetrafluoroethoxy, the 2,2,2-trifluoroethoxy, the trifluoromethoxy and preferably the difluoromethoxy radicals may be mentioned.
• "Predominantly" in this connection means that more than half of the hydrogen atoms are replaced by fluorine atoms.
• 1-2C-Alkylenedioxy represents, for example, the methylenedioxy [-0-CH 2 -0-] and the ethylenedioxy [-0-CH 2 -CH 2 -0-] radicals.
• R3 and R31 together have the meaning 1-4C-alkylene
• the positions 1 and 4 in compounds of the formula I are linked to one another by a 1-4C-alkylene bridge, 1-4C-alkylene representing straight-chain or branched alkylene radicals having 1 to 4 carbon atoms.
• 1-4C-alkylene representing straight-chain or branched alkylene radicals having 1 to 4 carbon atoms. Examples which may be mentioned are the radicals methylene [-CH 2 -], ethylene [-CH 2 -CH 2 -], trimethylene [-CH 2 -CH 2 -CH 2 -], 1 ,2-dimethylethylene [-CH(CH 3 )-CH(CH 3 )-] and isopropylidene [-C(CH 3 ) 2 -].
• Halogen within the meaning of the invention is bromine, chlorine or fluorine.
• 3-7C-Cycloalkyl represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, of which cyclopropyl, cyclobutyl and cyclopentyl are preferred.
• 3-7C-Cycloalkylmethyl represents a methyl radical which is substituted by one of the abovementioned 3-7C-cycloalkyl radicals.
• the 3-5C-cycloalkylmethyl radicals cyclopropylmethyl, cyclobutyl- methyl and cyclopentylmethyl may be mentioned.
• 1-4C-Alkoxy-1-4C-alkyl represents one of the abovementioned 1-4C-alkyl radicals, which is substituted by one of the abovementioned 1-4C-alkoxy radicals. Examples which may be mentioned are the meth- oxymethyl, the methoxyethyl and the isopropoxyethyl radicals.
• Phenyl-1-4C-alkyl represents one of the abovementioned, phenyl-substituted 1-4C-alkyl radicals. Examples which may be mentioned are the phenethyl and the benzyl radicals.
• 1-4C-Alkylcarbonyl represents a radical which, in addition to the carbonyl group, contains one of the abovementioned 1-4C-alkyl radicals.
• An example which may be mentioned is the acetyl radical.
• 3-7C-Cycloalkylcarbonyl represents a radical which, in addition to the carbonyl group, contains one of the abovementioned 3-7C-cycloalkyl radicals.
• An example which may be mentioned is the cyclopentyl- carbonyl radical.
• 3-7C-Cycloalkylmethylcarbonyl represents a radical which, in addition to the carbonyl group, contains one of the abovementioned 3-7C-cycloalkylmethyl radicals.
• An example which may be mentioned is the cyclopropylmethylcarbonyl radical.
• 1-4C-Alkoxycarbonyl represents a carbonyl group to which one of the abovementioned 1-4C-alkoxy radicals is bonded. Examples which may be mentioned are the methoxycarbonyl [CH 3 0-C(0)-J and the ethoxycarbonyl [CH 3 CH 2 0-C(0)-] radicals.
• 1-4C-Alkylcarbonyloxy represents a carbonyioxy group to which one of the abovementioned 1-4C-alkyl radicals is bonded.
• An example which may be mentioned is the acetoxy radical [CH 3 C(0)-0-].
• mono- or di-1-4C-alkylaminocarbonyl radicals contain one of the abovementioned mono- or di-1-4C-alkylamino radicals. Examples which may be mentioned are the N-methyl-, the N,N-dimethyl-, the N-ethyl-, the N-propyl-, the N,N-diethyl- and the N-isopropylamino- carbonyl radicals.
• mono- or di-1-4C-alkylamino radicals contain one or two of the above- mentioned 1-4C-alkyl radicals.
• Di-1-4C-alkylamino is preferred and here, in particular, dimethyl-, di- ethyl- or diisopropylamino.
• a 1-4C-alkylcarbonylamino radical for example, the propionylamino [C 3 H 7 C(0)NH-] and the ace- tylamino [CH 3 C(0)NH-] radicals may be mentioned.
• phenyl radicals substituted by R6, R13 and R20 which may be mentioned are 3-phenoxy- phenyl, 4-phenoxyphenyI, 3-benzyloxyphenyl, 4-benzyloxyphenyl, 3-phenethoxyphenyl, 4-phenethoxy- phenyl, 3-benzyloxy-4-methoxyphenyl, 4-benzyloxy-3-methoxyphenyl, 3-benzyloxy-5-methoxyphenyl, 4-benzyloxy-3-cyclopropylmethoxyphenyl, 3-cyclopentyloxyphenyl, 4-cyclopentyloxyphenyl, 4-cyclo- hexyloxyphenyl, 3-cyclohexyloxyphenyl, 3-cyclopropylmethoxyphenyl, 4-cyclopropylmethoxyphenyl, 4-cyclopropylmethoxyphenyl, 4-cyclopropylmethoxyphenyl, 4-cyclopropylmethoxyphenyl, 4-cyclopropy
• Possible salts for compounds of the formula I -depending on substitution - are all acid addition salts or all salts with bases. Particular mention may be made of the pharmacologically tolerable salts of the inorganic and organic acids and bases customarily used in pharmacy.
• water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 3-hydroxy-2-naphthoic acid, it being possible to employ the acids in salt preparation - depending on whether a mono- or polybasic acid is concerned and depending on which salt is desired - in an equimolar quantitative ratio or one differing therefrom.
• acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, n
• salts with bases are also suitable.
• examples of salts with bases which may be mentioned are alkali metal (lithium, sodium, potassium) or calcium, aluminum, magnesium, titanium, ammonium, meglumine or guanidinium salts, where here too the bases are employed in salt preparation in an equimolar quantitative ratio or one differing therefrom.
• Pharmacologically intolerable salts which can initially be obtained, for example, as process products in the preparation of the compounds according to the invention on an industrial scale are converted into pharmacologically tolerable salts by processes known to the person skilled in the art.
• the compounds according to the invention and their salts when they are isolated, for example, in crystalline form, can contain various amounts of solvents.
• the invention therefore also comprises all solvates and in particular all hydrates of the compounds of the formula I, and also all solvates and in particular all hydrates of the salts of the compounds of the formula I.
• One embodiment (embodiment a) of the invention are compounds of the formula I, in which R1 is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy, R2 is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy,
• R3 is hydrogen
• R31 is hydrogen
• R4 is hydrogen or 1-2C-alkyl
• R5 is hydrogen
• R51 is hydrogen, or in which
• R6 is 0-R7, S-R8, C(0)-R9, CH 2 -R10, S0 2 -aryl, 0-S(0) 2 -R11 , pyrrolidin-1-yl, pyrrolidin-1-yl-2-one or pyrrolidin-1-yl-2,5-dione, where
• R7 is 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, 1-4C-alkoxy-1-4C-alkyl, aryl or phenyl-1-4C-alkyI,
• R8 is hydrogen, 1-4C-alkyl, acetyl, phenylcarbonyl, trifluoromethyl or phenyl,
• R9 is 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, 1-piperidinyl, 1-piperazinyl, 4-methylpipe- razinyl, 4-morphoIinyl or aryl,
• R10 is halogen, carboxyl, 1-4C-alkoxy, phenoxy, 1-4C-alkoxycarbonyl, aminocarbonyl, mono- or di-1- 4C-alkylaminocarbonyl, N(R15)R16 or 1-4C-alkylcarbonylamino, and
• R11 is 1-4C-alkyl, mono- or di-1-4C-alkylamino or aryl, aryl is phenyl, pyridyl or R12-substituted phenyl, where
• R12 is halogen, carboxyl, nitro, amino, cyano, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy,
• R13 is hydrogen, hydroxyl, halogen, cyano, nitro, amino, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, phenyl, phenyl-1-4C-alkyl, C(0)-OR14, C(0)-N(R15)R16, N(R17)R18, S(0) 2 -R19, S(0) 2 -N(R15)R16 or has one of the meanings of R6, where
• R14 is hydrogen or 1-4C-alkyl
• R15 is hydrogen or 1-4C-alkyl
• R16 is hydrogen, 1-4C-alkyl or aryl, or where R15 and R16, together and including the nitrogen atom to which both are bonded, are a 1-piperidyl, 1-piperazinyl, 1-methylpiperazin-4-yl or 4-morpholinyl radical,
• R17 is hydrogen, 1-4C-alkyl, S(0) 2 -R19 or S(0) 2 -aryl,
• R18 is 1-4C-alkyl, 1-4C-alkylcarbonyl, 3-7C-cycloalkylcarbonyl, 3-7C-cycloalkylmethylcarbonyl, S(0) 2 -R19 or S(0) 2 -aryl, and
• R19 is 1-4C-alkyl
• R20 is hydrogen, hydroxyl, halogen, nitro, amino, 1-4C-alkyI, trifluoromethyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkyl-methoxy, carboxyl, 1-4C-alkoxycarbonyl or 1-4C-alkylcarbonyloxy, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
• Compounds of the formula I of embodiment a to be emphasized are those in which
• R1 is 1-2C-alkoxy
• R2 is 1-2C-alkoxy
• R3, R31, R4, R5 and R51 are hydrogen
• R6 is 0-R7, S-R8, C(0)-R9, CH 2 -R10, S(0) 2 -phenyl, 0-S(0) 2 -R11 , pyrrolidin-1-yl, pyrrolidin-1 -yl-2- one or pyrrolidin-1 -yl-2,5-dione, where R7 is 3-5C-cycloalkyl, 3-5C-cyc!oalkylmethyl, 1-2C-alkoxy-1-2C-alkyl, aryl or phenyl-1-2C-alkyl, R8 is phenyl,
• R9 is 1-4C-alkyI, 3-5C-cycloaIkylmethyI, 1-piperidinyl or aryl
• R10 is halogen, 1 -4C-alkoxycarbonyl or N(R15)R16
• R11 is methyl or 4-methylphenyl
• aryl is phenyl, pyridyl or R12-substituted phenyl, where R12 is 1-4C-alkyl, 1-4C-alkoxy, halogen, nitro or cyano
• R15 is 1-4C-alkyl
• R16 is 1 -4C-alkyl, or where R15 and R16, together and including the nitrogen atom to which both are bonded, are a 1-piperidinyl,
• R13 is hydrogen, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-2C-alkoxy, or 1-4C- alkylcarbonylamino and R20 is hydrogen, or
• R13 is hydrogen
• R20 is 3-5C-cycloalkoxy or 3-5C-cycloalkylmethoxy, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
• R1 is 1-2C-alkoxy
• R2 is 1-2C-alkoxy
• R3, R31 , R4, R5 and R51 are hydrogen
• R6 is 0-R7, S-R8, C(0)-R9, CH 2 -R10, S(0) 2 -phenyl, 0-S(0) 2 -R11 , pyrrolidin-1 -yl or pyrrolidin-1 -yl-
• R7 is cyclobutyl, cyclopentyl, cyclopropylmethyl, 2-methoxyethyl, phenyl, 4-methoxyphenyl, benzyl, phenethyl or pyridyl
• R8 is phenyl
• R9 is methyl, ethyl, isobutyl, cyclopropylmethyl, 1-piperidinyl or aryl
• R10 is methoxycarbonyl, morpholin-4-yl or 1-methylpiperazin-4-yl
• R11 is methyl or 4-methylphenyl
• aryl is phenyl, pyridyl or R12-substituted phenyl, in which
• R12 is methoxy, halogen, nitro or cyano, and in which either
• R13 is hydrogen, methoxy, ethoxy, difluoromethoxy or acetylamino and
• R20 is hydrogen, or
• R13 is hydrogen
• R20 is cyclopropylmethoxy, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
• R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy,
• R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy, or in which
• R1 and R2 together are a 1-2C-alkylenedioxy group
• R3 is hydrogen or 1-4C-alkyl
• R31 is hydrogen or 1-4C-alkyl, or in which
• R3 and R31 together are a 1-4C-alkylene group
• R4 is hydrogen or 1-4C-alkyl
• R5 is hydrogen
• R51 is hydrogen, or in which
• R6 is 0-R7, S-R8, C(0)-R9, CH 2 -R10 or 0-S(0) 2 -R11 , where
• R7 is 3-7C-cycloalkyI, 3-7C-cycloalkylmethyl, aryl or phenyl-1-4C-alkyl,
• R8 is hydrogen, 1-4C-alkyl, 1-4C-alkylcarbonyl, trifluoromethyl, difluoromethyl, trichloromethyl or phenyl,
• R9 is 1-4C-alkyl, 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-methylpiperazinyl, 4-morpholinyl or aryl,
• R10 is hydroxyl, halogen, cyano, carboxyl, 1-4C-alkoxy, phenoxy, 1-4C-alkoxycarbonyl, aminocarb- onyl, mono- or di-1-4C-alkylaminocarbonyl, N(R15)R16 or 1-4C-alkylcarbonylamino, and
• R11 is 1 -4C-alkyl, amino, mono- or di-1 -4C-alkylamino or aryl, aryl is phenyl, pyridyl or R12-substituted phenyl, where
• R12 is hydroxyl, halogen, carboxyl, nitro, amino, cyano, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonylamino, 1-4C-aIkylcarbonyloxy or aminocarbonyl
• R13 is hydrogen, hydroxyl, halogen, cyano, nitro, amino, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, phenyl, phenyl-1-4C-alkyf, C(0)-OR14, C(0)-N(R15)R16, N(R17)R18, S(0) 2 -R19, S(0) 2 -N(R15)R16 or has one of the meanings of R6, where
• R14 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl,
• R15 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or 3-7C-cycloalkylmethyl,
• R16 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl or aryl, or where R15 and R16, together and including the nitrogen atom to which both are bonded, are a 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-methylpiperazin-1-yl, 1-hexahydroazepinyl or 4-morpholinyl radical,
• R17 is hydrogen, 1 -4C-alkyl, S(0) 2 -R19 or S(0) 2 -aryl,
• R18 is 1-4C-alkyl, 1-4C-alkylcarbonyl or S(0) 2 -R19 or S(0) 2 -aryl, and
• R19 is 1-4C-alkyl
• R20 is hydrogen, hydroxyl, halogen, nitro, amino, 1-4C-alkyl, trifluormethyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, CH 2 -R10, carboxyl, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyloxy, 1-4C-alkylcarbonylamino or aminocarbonyl, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
• R1 is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy,
• R2 is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-2C-aikoxy,
• R3 is hydrogen
• R31 is hydrogen
• R4 is hydrogen or 1-2C-alkyl
• R5 is hydrogen
• R51 is hydrogen, or in which
• R6 is 0-R7, S-R8, C(0)-R9, CH 2 -R10 or 0-S(0) 2 -R11 , where
• R7 is 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, aryl or phenyl-1-4C-alkyl,
• R8 is hydrogen, 1-4C-alkyl, acetyl, trifluoromethyl or phenyl,
• R9 is 1-4C-alkyl, 1-piperidinyl, 1-piperazinyl, 4-methylpiperazinyl, 4-morpholinyl or aryl,
• R10 is halogen, carboxyl, 1-4C-alkoxy, phenoxy, 1-4C-aIkoxycarbonyl, aminocarbonyl, mono- or di-1- 4C-alkylaminocarbonyl, N(R15)R16 or 1-4C-alkylcarbonyIamino, and
• R11 is 1-4C-alkyl, mono- or di-1-4C-alkylamino or aryl, aryl is phenyl, pyridyl or R12-substituted phenyl, where
• R12 is halogen, carboxyl, nitro, amino, cyano, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy,
• R13 is hydrogen, hydroxyl, halogen, cyano, nitro, amino, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, phenyl, phenyl-1-4C-alkyl, C(0)-OR14, C(0)-N(R15)R16, N(R17)R18, S(0) 2 -R19, S(0) 2 -N(R15)R16 or has one of the meanings of R6, where
• R14 is hydrogen or 1-4C-alkyl
• R15 is hydrogen or 1 -4C-alkyl
• R16 is hydrogen, 1-4C-alkyl or aryl, or where R15 and R16, together and including the nitrogen atom to which both are bonded, are a 1-piperidyl, 1-piperazinyl, 4-methylpiperazin-1-yl or 4-morpholinyl radical,
• R17 is hydrogen, 1-4C-alkyl, S(0) 2 -R19 or S(0) 2 -aryl,
• R18 is 1-4C-alkyl, 1-4C-alkylcarbonyl, S(0) 2 -R19 or S(0) 2 -aryl, and
• R19 is 1-4C-alkyl
• R20 is hydrogen, hydroxyl, halogen, nitro, amino, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, carboxyl, 1-4C-alkoxycarbonyl or 1-4C-alkylcarbonyloxy, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
• R1 is 1-2C-aIkoxy
• R2 is 1-2C-alkoxy
• R3, R31 , R4, R5 and R51 are hydrogen
• R6 is 0-R7, S-R8, C(0)-R9, CH 2 -R10 or 0-S(0) 2 -R11 , where
• R7 is 3-5C-cycloalkyl, 3-5C-cycloalkylmethyl, phenyl or phenyl-1-2C-alkyl,
• R8 is phenyl
• R9 is methyl, 1-piperidinyl or phenyl
• R10 is halogen, 1-4C-alkoxycarbonyl or N(R15)R16 and
• R11 is methyl or 4-methylphenyl
• R15 is 1-4C-alkyl
• R16 is 1-4C-alkyl, or where
• R15 and R16 together and including the nitrogen atom to which both are bonded, are a 1-piperidinyl
• R13 is hydrogen, methoxy or ethoxy and R20 is hydrogen, or R13 is hydrogen and R20 is 3-5C-cycloalkoxy or 3-5C-cycloalkylmethoxy, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
• R1 is 1-2C-alkoxy
• R2 is 1-2C-alkoxy
• R3, R31 , R4, R5 and R51 are hydrogen
• R6 is 0-R7, S-R8, C(0)-R9, CH 2 -R10 or 0-S(0) 2 -R11 , where
• R7 is cyclopentyl, cyclopropylmethyl, phenyl, benzyl or phenethyl,
• R8 is phenyl
• R9 is methyl, 1-piperidinyl or phenyl
• R10 is halogen, methoxycarbonyl, morpholin-4-yl or 1-methylpiperazin-4-yl and
• R11 is methyl or 4-methylphenyl, and in which either
• R13 is hydrogen or methoxy
• R20 is hydrogen, or
• R13 is hydrogen
• R20 is cyclopropylmethoxy and the salts, the N-oxides and the salts of the N-oxides of these compounds.
• a further embodiment (embodiment c) of the invention are compounds of the formula I in which
• R1 is 1-2C-alkoxy, 3-5C-cycIoalkoxy, 3-5C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy,
• R2 is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy,
• R3 is hydrogen
• R31 is hydrogen
• R4 is hydrogen or 1-2C-alkyl
• R5 is hydrogen
• R51 is hydrogen, or where
• R6 is 0-R7, S-R8, C(0)-R9, CH 2 -R10, S(0) 2 -phenyl or 0-S(0) 2 -R11 , where
• R7 is 3-5C-cycloalkyl, 3-5C-cycloalkylmethyl, 1-2C-alkoxy-1-2C-alkyl, aryl or phenyl-1-2C-alkyl,
• R8 is phenyl
• R9 is 1-4C-alkyl, 3-5C-cycloalkylmethyl, 1-piperidinyl or aryl,
• R10 is halogen and R11 is 1-4C-alkyl or aryl, aryl is phenyl or R12-substituted phenyl, where R12 is halogen, nitro, 1-4C-alkyl or 1-4C-alkoxy,
• R13 is hydrogen, 1-4C-alkoxy, 1-4C-alkylcarbonylamino or completely or predominantly fluorine-substituted 1-2C-alkoxy
• R20 is hydrogen, 3-5C-cycloalkoxy or 3-5C-cycloalkylnnethoxy, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
• R6 is 0-R7, S-R8, C(0)-R9, CH 2 -R10, S(0) 2 -phenyl or 0-S(0) 2 -R11 , where R7 is 3-5C-cycloalkyl, 3-5C-cycloalkylmethyl, 1 -2C-alkoxy-1 -2C-alkyl, aryl or phenyl-1 -2C-alkyl, R8 is phenyl,
• R9 is 1-4C-alkyl, 3-5C-cycloalkylmethyl, 1-piperidinyl or aryl, R10 is halogen, R11 is 1-4C-alkyl or aryl, aryl is phenyl or R12-substituted phenyl, where R12 is halogen, nitro, 1-4C-alkyl or 1-4C-alkoxy,
• R13 is hydrogen, 1-4C-alkoxy, 1-4C-alkylcarbonylamino or completely or predominantly fluorine-substituted 1-2C-alkoxy
• R20 is hydrogen, 3-5C-cycloalkoxy or 3-5C-cycloalkylmethoxy, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
• R1 is 1-2C-alkoxy
• R2 is 1-2C-alkoxy
• R3, R31 , R4, R5 and R51 are hydrogen
• R6 is acetyl, ethylcarbonyl, isobutylcarbonyl, cyclopropylmethylcarbonyl, benzoyl, 4-methoxyphen- ylcarbonyl, 4-chlorophenylcarbonyl, 3-chloro-phenylcarbonyl, 4-nitrophenylcarbonyl, thio-phen- oxy, phenoxy, 4-methoxyphenyloxy, benzyloxy, phenethyloxy, methylsulfonyloxy, 4-methylphen- ylsulfonyloxy, phenylsulfonyl, 4-chloromethyl or piperid-1-ylcarbonyl,
• R13 is hydrogen
• R20 is hydrogen, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
• Further preferred compounds of the formula I of embodiment c are those in which
• R1 is 1-2C-alkoxy
• R2 is 1-2C-alkoxy
• R3, R31 , R4, R5 and R51 are hydrogen
• R6 is benzyloxy, methoxyethoxy, cyclopropylmethoxy or cyclobutoxy, and in which either
• R13 is methoxy, ethoxy or acetylamino
• R20 is hydrogen, or
• R13 is hydrogen
• R20 is cyclopropylmethoxy, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
• R1 is methoxy
• R2 is methoxy or ethoxy
• R3, R31 , R4, R5 and R51 are hydrogen
• R6 is acetyl, benzoyl, phenoxy or piperid-1-ylcarbonyl,
• R13 is hydrogen
• R20 is hydrogen, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
• R1 is methoxy
• R2 is methoxy or ethoxy
• R3, R31 , R4, R5 and R51 are hydrogen
• R6 is cyclopropylmethoxy or cyclobutoxy, and in which either
• R13 is methoxy or ethoxy
• R20 is hydrogen, or
• R13 is hydrogen
• R20 is cyclopropylmethoxy, and the salts, the N-oxides and the salts of the N-oxides of these compounds.
• the compounds of the formula I are chiral compounds having chiral centers in positions 4a and 10b and, depending on the meaning of the substituents R3, R31 , R4, R5 and R51 , further chiral centers in the positions 1 , 2, 3 and 4. Numbering:
• the invention therefore comprises all conceivable pure diastereomers and pure enantiomers and their mixtures in any mixing ratio, including the racemates.
• the compounds of the formula I are preferred in which the hydrogen atoms in positions 4a and 10b are cis to one another.
• the pure cis enantiomers are particularly preferred.
• the enantiomers can be separated in a manner known per se (for example by preparation and separation of appropriate diastereoisomeric compounds).
• an enantiomer separation is carried out at the stage of the starting compounds of the formula IV
• racemic compounds of the formula IV for example by means of salt formation of the racemic compounds of the formula IV with optically active carboxylic acids.
• optically active carboxylic acids examples which may be mentioned in this connection are the enantiomeric forms of mandelic acid, tartaric acid, O.O'-dibenzoyltartaric acid, camphoric acid, quinic acid, glutamic acid, malic acid, camphorsulfonic acid, 3-bromocamphorsulfonic acid, ⁇ -methoxyphenylacetic acid, ⁇ -meth- oxy- -trifluoromethylphenylacetic acid and 2-phenylpropionic acid.
• enantiomerically pure starting compounds of the formula IV can also be prepared via asymmetric syntheses.
• the process comprises cyclocondensing compounds of the formula II
• R1 , R2, R3, R31 , R4, R5, R51 , R6, R13 and R20 have the meanings indicated above, and, optionally, then converting the compounds of the formula I obtained into their salts, or, optionally, then converting salts of the compounds of the formula I obtained into the free compounds.
• R12 and/or R13 and/or R20 are an ester group
• the corresponding acids can be obtained by acidic or alkaline hydrolysis, or the corresponding amides can be prepared by reaction with suitably substituted amines;
• R12 and/or R20 are a 1-4C-alkylcarbonyloxy group, the corresponding hydroxyl compounds can be obtained by acidic or alkaline hydrolysis; c) one or more of the radicals R10, R12, R13 and R20 are a nitro group, the corresponding amino compounds, which, for their part, can again be further derivatized, can be obtained by selective catalytic hydrogenation.
• the compounds of the formula I can be converted, optionally, into their N-oxides, for example with the aid of hydrogen peroxide in methanol or with the aid of m-chloroperoxybenzoic acid in di- chloromethane.
• the person skilled in the art is familiar on the basis of his/her expert knowledge with the reaction conditions which are specifically necessary for carrying out the N-oxidation.
• cyclocondensation is carried out in a manner known per se to the person skilled in the art, according to Bischler-Napieralski (e.g. as described in J. Chem. Soc, 1956, 4280-4282) in the presence of a suitable condensing agent, such as, for example, polyphosphoric acid, phosphorus pentachloride, phosphorus pentoxide or preferably phosphorus oxychloride, in a suitable inert solvent, e.g.
• a chlorinated hydrocarbon such as chloroform
• a cyclic hydrocarbon such as toluene or xylene
• another inert solvent such as acetonitrile
• an excess of condensing agent preferably at elevated temperature, in particular at the boiling temperature of the solvent or condensing agent used.
• R6, R13 and R20 have the meanings indicated above and X represents a suitable leaving group, preferably a chlorine atom.
• acylation or benzoylation is carried out as described in. the following examples or as in J. Chem. Soc. (C), 1971 , 1805-1808.
• Compounds of the formula III and compounds of the formula IV are either known or can be prepared in a known manner.
• the compounds of the formula IV can be prepared, for example, from compounds of the formula V,
• R1 , R2, R3, R31 , R4, R5 and R51 have the abovementioned meanings, by reduction of the nitro group.
• the reduction can be carried out, for example, by catalytic hydrogenation, e.g. in the presence of Ra- ney nickel, in a lower alcohol such as methanol or ethanol at room temperature and under normal or elevated pressure.
• a catalytic amount of an acid such as, for example, hydrochloric acid
• the reduction is carried out using metals such as zinc or iron with organic acids such as acetic acid or mineral acids such as hydrochloric acid.
• the compounds of the formula IV in which R1 , R2, R3, R31 and R4 have the meanings indicated above and R5 and R51 together represent an additional bond can be prepared from the corresponding compounds of the formula V by selective reduction of the nitro group in a manner known to the person skilled in the art, for example in the presence of Raney nickel in a lower alcohol as solvent using hydra- zine hydrate as a hydrogen donor.
• the compounds of the formula V in which R1 , R2, R3, R31 and R4 have the meanings indicated above and R5 and R51 are hydrogen, are either known or can be prepared from corresponding compounds of the formula V in which R5 and R51 together are an additional bond.
• the reaction can be carried out in a manner known to the person skilled in the art, preferably by hydrogenation in the presence of a catalyst, such as, for example, palladium on active carbon, e.g. as described in J. Chem. Soc. (C), 1971, 1805-1808.
• a catalyst such as, for example, palladium on active carbon, e.g. as described in J. Chem. Soc. (C), 1971, 1805-1808.
• the compounds of the formula V, in which R5 and R51 together are an additional bond are either known or can be obtained by the reaction of compounds of the formula VI,
• R3, R31 and R4 have the meanings mentioned above.
• the cycloaddition is in this case carried out in a manner known to the person skilled in the art according to Diels-Alder, e.g. as described in J. Amer. Chem. Soc. 1957, 79, 6559 or in J. Org. Chem. 1952, 17, 581 or as described in the following examples.
• the compounds of the formulae VI and VII are either known or can be prepared in a known manner.
• the compounds of the formula VI can be prepared, for example, in a manner known to the person skilled in the art from corresponding compounds of the formula VIII as described, for example, in J. Chem. Soc. 1951, 2524 or in J. Org. Chem. 1944, 9, 170 or as described in the following examples.
• R1 and R2 have the meanings indicated above, are either known or can be prepared in a manner known to the person skilled in the art, as described, for example, in Ber. Dtsch. Chem. Ges. 1925, 58, 203.
• the isolation and purification of the substances according to the invention is carried out in a manner known per se, e.g. by distilling off the solvent in vacuo and recrystallizing the resulting residue from a suitable solvent or subjecting it to one of the customary purification methods, such as, for example, column chromatography on suitable support material.
• Salts are obtained by dissolving the free compound in a suitable solvent (e.g. a ketone, such as acetone, methyl ethyl ketone or methyl isobutyl ketone, an ether, such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol such as ethanol or isopropanol) which contains the desired acid or base, or to which the desired acid or base is then added.
• the salts are obtained by filtering, reprecipitating, precipitating with a nonsolvent for the addition salt or by evaporating the solvent. Salts obtained can be converted by alkalization or by acidification into the free compounds, which in turn can be converted into salts. In this way, pharmacologically intolerable salts can be converted into pharmacologically tolerable salts.
• (+/-)-cis-1-methoxy-2-ethoxy-4-(2-aminocyclohexyl)benzene and 100.0 g of (+)-0,0 ' -dibenzo- yltartaric acid are dissolved in 900 ml of dioxane and 900 ml of methyl isobutyl ketone and the solution is stirred overnight at RT.
• the solid is filtered off with suction, washed by stirring 500 ml of acetone and 1000 ml of ethyl acetate, filtered off with suction again and dried.
• the product is treated with 600 ml of 2N sodium hydroxide solution and extracted with ethyl acetate.
• (+/-)-cis-1 ,2-dimethoxy-4-(2-nitrocyclohexyl)benzene and 120 g of zinc powder or granules are suspended in 1300 ml of ethanol. 220 ml of acetic acid are added dropwise at boiling heat. The precipitate is filtered off with suction and washed with ethanol, and the filtrate is concentrated under reduced pressure. The residue is taken up in hydrochloric acid and extracted with toluene. The aqueous phase is rendered alkaline using 50% strength sodium hydroxide solution, the precipitate is filtered off with suction and the filtrate is extracted with toluene. The organic phase is dried using sodium sulfate and concentrated. 98 g of the title compound are obtained as a crystallizing oil.
• the compounds according to the invention have valuable pharmacological properties which make them commercially utilizable.
• selective cyclic nucleotide phosphodiesterase (PDE) inhibitors namely of type 4
• they are suitable on the one hand as bronchial therapeutics (for the treatment of airway obstructions on account of their dilating but also on account of their respiratory rate- or respiratory drive- increasing action) and for the elimination of erectile dysfunction on account of the vasodilating action, but on the other hand especially for the treatment of disorders, in particular of inflammatory nature, e.g.
• the compounds according to the invention are distinguished here by low toxicity, good en- teral absorption (high bioavailability), a large therapeutic breadth and the absence of significant side- effects.
• the compounds according to the invention can be employed in human and veterinary medicine and therapeutics, where they can be used, for example, for the treatment and prophylaxis of the following illnesses: acute and chronic (in particular inflammatory and allergen-induced) airway disorders of various origins (bronchitis, allergic bronchitis, bronchial asthma, emphysema, COPD); dermatoses (especially of proliferative, inflammatory and allergic type) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritus in the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and wide-area pyodermias, endogenous and exogenous acne, acne rosacea
• disorders of the arthritis type rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic conditions
• disorders of the immune system AIDS, multiple sclerosis
• graft-versus-host reactions transplant rejection reactions
• symptoms of shock [septic shock, endotoxin shock, gram-negative sepsis, toxic shock syndrome and ARDS (adult respiratory distress syndrome)]
• generalized inflammations in the gastrointestinal area Crohn's disease and ulcerative colitis
• disorders of the heart which can be treated by PDE inhibitors, such as, for example, cardiac insufficiency, or disorders which
• diabetes insipidus and disorders in connection with disturbances of brain metabolism such as, for example, cerebral senility, senile dementia (Alzheimer's dementia), multiin- farct dementia or alternatively disorders of the CNS, such as, for example, depressions or arterioscle- rotic dementia.
• a further subject of the invention is a process for the treatment of mammals, including man, which are suffering from one of the abovementioned illnesses.
• the process comprises administering to the sick mammal a therapeutically efficacious and pharmacologically tolerable amount of one or more of the compounds according to the invention.
• the invention further relates to the compounds according to the invention for use in the treatment of mammals, including man, which are suffering from one of the abovementioned illnesses.
• the process comprises administering to the sick mammal a therapeutically efficacious and pharmacologically tolerable amount of one or more of the compounds according to the invention.
• the invention further relates to the compounds according to the invention for use in the treatment and/or prophylaxis of illnesses, in particular the illnesses mentioned.
• the invention likewise relates to the use of the compounds according to the invention for the production of medicaments which are employed for the treatment and/or prophylaxis of the illnesses mentioned.
• Medicaments for the treatment and/or prophylaxis of the illnesses mentioned which contain one or more of the compounds according to the invention, are furthermore a subject of the invention.
• a further subject of the invention is a commercial product, consisting of a customary secondary pack, a primary pack containing the medicament (for example an ampoule or a blister pack) and, optionally, a pack insert, the medicament exhibiting antagonistic action against cyclic nucleotide phosphodiester- ases of type 4 (PDE4) and leading to the attenuation of the symptoms of illnesses which are connected with cyclic nucleotide phosphodiesterases of type 4, and the suitability of the medicament for the prophylaxis or treatment of illnesses which are connected with cyclic nucleotide phosphodiesterases of the type 4 being indicated on the secondary pack and/or on the pack insert of the commercial product, and the medicament containing one or more compounds of the formula I according to the invention.
• the secondary pack, the primary pack containing the medicament and the pack insert otherwise comply with what would be regarded as standard to the person skilled in the art for medicaments of this type.
• the medicaments are prepared by processes which are known per se and familiar to the person skilled in the art.
• the compounds according to the invention are preferably also administered by inhalation.
• these are either administered directly as a powder (preferably in micronized form) or by nebulization of solutions or suspensions which contain them.
• a powder preferably in micronized form
• nebulization of solutions or suspensions which contain them are administered directly as a powder (preferably in micronized form) or by nebulization of solutions or suspensions which contain them.
• the compounds according to the invention are in particular used in the form of those medicaments which are suitable for topical application.
• suitable pharmaceutical formulations which may be mentioned are, for example, powders, emulsions, suspensions, sprays, oils, ointments, fatty ointments, creams, pastes, gels or solutions.
• the medicaments according to the invention are prepared by methods known per se. Dosage of the active compounds takes place in the order of magnitude customary for PDE inhibitors. Thus topical application forms (such as, for example, ointments) for the treatment of dermatoses contain the active compounds in a concentration of, for example, 0.1-99%.
• the dose for administration by inhalation is customarily between 0.1 and 3 mg per day.
• the customary dose in the case of systemic therapy (p.o. or i.v.) is between 0.03 and 3 mg per kilogram per day.
• the activation of inflammatory cells has particular importance.
• the FMLP N-formyl-methionyl-leucyl-phenylalanine
• su- peroxide production of neutrophilic granulocytes may be mentioned, which can be measured as lumi- nol-potentiated chemoluminescence [McPhail LC, Strum SL, Leone PA and Sozzani S, The neutrophil respiratory burst mechanism.
• McPhail LC, Strum SL, Leone PA and Sozzani S The neutrophil respiratory burst mechanism.
• Coffey RG Marcel Decker, Inc. New York-Basle-Hong Kong
• Substances which inhibit chemoluminescence and cytokine secretion and the secretion of inflammatory mediators on inflammatory cells are those which inhibit PDE4.
• This isoenzyme of the phosphodi- esterase families is particularly represented in granulocytes. Its inhibition leads to an increase in the intracellular cyclic AMP concentration and thus to the inhibition of cell activation.
• PDE4 inhibition by the substances according to the invention is thus a central indicator of the suppression of inflammatory processes (Glembycz MA, Can isoenzyme-selective phosphodiesterase inhibitors render broncho- dilatory therapy redundant in the treatment of bronchial asthma?. Biochem Pharmacol 1992, 43, 2041- 2051; Torphy TJ et al., Phosphodiesterase inhibitors: new opportunities for treatment of asthma. Thorax 1991 , 46, 512-523; Schudt C et al., Zardaverine: a cyclic AMP PDE 3/4 inhibitor.
• the activity test was carried out according to the method of Bauer and Schwabe, which was adapted to microtiter plates (Naunyn-Schmiedeberg's Arch. Pharmacol. 1980, 311 , 193-198).
• the PDE reaction takes place in the first step here, in a second step, the resulting 5'-nucleotide is cleaved by a 5'-nucloe- tidase of the snake venom of Crotalus atrox to the uncharged nucleoside.
• the nucleo- side is separated from the remaining charged substrate on ion-exchange columns. The columns are eluted directly into minivials, into which 2 ml of scintillator fluid are additionally added, for counting using 2 ml of 30 mM ammonium formate (pH 6.0).
• inhibitory values determined for the compounds according to the invention [inhibitory concentration as -log IC 50 (mol/l)] follow from the following Table A, in which the numbers of the compounds correspond to the numbers of the examples.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Pulmonology (AREA)
• Dermatology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Urology & Nephrology (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Cardiology (AREA)
• Otolaryngology (AREA)
• Physical Education & Sports Medicine (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Toxicology (AREA)
• Heart & Thoracic Surgery (AREA)
• Transplantation (AREA)
• Gynecology & Obstetrics (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Ophthalmology & Optometry (AREA)
• Epidemiology (AREA)

Priority Applications (22)

Applications Claiming Priority (2)

Publications (1)

Family

ID=8237351

Family Applications (1)

Country Status (32)

Cited By (14)

Families Citing this family (26)

Citations (4)

Family Cites Families (8)

• 2000
  • 2000-01-12 DK DK00901534T patent/DK1147089T3/da active
  • 2000-01-12 ID IDW00200101411A patent/ID29070A/id unknown
  • 2000-01-12 TR TR2001/01938T patent/TR200101938T2/xx unknown
  • 2000-01-12 AT AT00901534T patent/ATE312081T1/de active
  • 2000-01-12 IL IL14402600A patent/IL144026A0/xx active IP Right Grant
  • 2000-01-12 BR BRPI0007527-2A patent/BR0007527B1/pt not_active IP Right Cessation
  • 2000-01-12 DE DE60024581T patent/DE60024581T2/de not_active Expired - Lifetime
  • 2000-01-12 CZ CZ20012248A patent/CZ300366B6/cs not_active IP Right Cessation
  • 2000-01-12 SI SI200030806T patent/SI1147089T1/sl unknown
  • 2000-01-12 HU HU0105001A patent/HU227624B1/hu not_active IP Right Cessation
  • 2000-01-12 PL PL348925A patent/PL205670B1/pl unknown
  • 2000-01-12 US US09/889,144 patent/US6476025B1/en not_active Expired - Lifetime
  • 2000-01-12 ES ES00901534T patent/ES2254132T3/es not_active Expired - Lifetime
  • 2000-01-12 CN CNB008027951A patent/CN1152864C/zh not_active Expired - Fee Related
  • 2000-01-12 NZ NZ512872A patent/NZ512872A/en not_active IP Right Cessation
  • 2000-01-12 KR KR1020017008670A patent/KR100720906B1/ko not_active IP Right Cessation
  • 2000-01-12 EP EP05108689A patent/EP1650193A3/en not_active Withdrawn
  • 2000-01-12 JP JP2000593588A patent/JP4653314B2/ja not_active Expired - Fee Related
  • 2000-01-12 EA EA200100731A patent/EA003780B1/ru not_active IP Right Cessation
  • 2000-01-12 RS YUP-487/01A patent/RS50297B/sr unknown
  • 2000-01-12 SK SK980-2001A patent/SK286946B6/sk not_active IP Right Cessation
  • 2000-01-12 TR TR2005/01553T patent/TR200501553T2/xx unknown
  • 2000-01-12 EE EEP200100350A patent/EE05105B1/xx not_active IP Right Cessation
  • 2000-01-12 AU AU22896/00A patent/AU774868B2/en not_active Ceased
  • 2000-01-12 WO PCT/EP2000/000172 patent/WO2000042020A1/en not_active Application Discontinuation
  • 2000-01-12 CA CA002359440A patent/CA2359440C/en not_active Expired - Fee Related
  • 2000-01-12 EP EP00901534A patent/EP1147089B1/en not_active Expired - Lifetime
  • 2000-12-01 UA UA2001085778A patent/UA69436C2/uk unknown
• 2001
  • 2001-06-04 BG BG105561A patent/BG65126B1/bg unknown
  • 2001-06-14 ZA ZA200104864A patent/ZA200104864B/en unknown
  • 2001-06-27 IL IL144026A patent/IL144026A/en not_active IP Right Cessation
  • 2001-07-05 NO NO20013341A patent/NO320182B1/no not_active IP Right Cessation
  • 2001-08-02 HR HR20010578A patent/HRP20010578A2/hr not_active Application Discontinuation
• 2002
  • 2002-04-10 HK HK02102714.9A patent/HK1040997B/zh not_active IP Right Cessation
• 2006
  • 2006-02-14 CY CY20061100209T patent/CY1106436T1/el unknown

Patent Citations (4)

Also Published As

Similar Documents

Legal Events